Organ systems

MatriSys Bioscience to Present at the 4th Microbiome Movement Skin Health & Dermatology Summit

Retrieved on: 
Thursday, July 29, 2021
Organ systems, Acneiform eruptions, Cutaneous conditions, Medical specialties, Organs anatomy), Rosacea, Acne, Dermatitis, Atopic dermatitis, Dermatology, Skin flora, Richard Gallo

LA JOLLA, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced that the companys CEO, Philippe Calais, Pharm.D., Ph.D., will present at the 4th Microbiome Movement Skin Health & Dermatology Summit, which will be held virtually August 3-5, 2021.

Key Points: 
  • LA JOLLA, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced that the companys CEO, Philippe Calais, Pharm.D., Ph.D., will present at the 4th Microbiome Movement Skin Health & Dermatology Summit, which will be held virtually August 3-5, 2021.
  • MatriSys Bioscience is leading the discovery and clinical development of a novel class of biopharmaceuticals to transform the treatment of inflammatory skin diseases.
  • Our groundbreaking technology platform identifies beneficial bacteria derived from healthy human skin to treat the millions of children and adults suffering from difficult to treat chronic skin diseases.
  • In addition to our lead clinical program in patients with atopic dermatitis, we are also rapidly advancing therapeutics for acne and rosacea.

Glaucoma Epidemiology Forecasts to 2030: 10 Year Forecasts, 7MM Coverage, Total Prevalent Cases and Glaucoma Patients by Age Group - ResearchAndMarkets.com

Retrieved on: 
Friday, July 30, 2021
Managed care, Health, Blindness, Glaucoma, Ophthalmology, Vision, Organ systems, Normal tension glaucoma, Canine glaucoma

The total diagnosed prevalent population of Glaucoma in the 7MM was 10,104,188 in 2020 , which is expected to increase in the forecast period.

Key Points: 
  • The total diagnosed prevalent population of Glaucoma in the 7MM was 10,104,188 in 2020 , which is expected to increase in the forecast period.
  • Among the European five countries, Germany had the highest diagnosed prevalent population of Glaucoma with 1,042,465 cases, followed by Italy and France in 2020.
  • Among the major types of Glaucoma, i.e., open-angle and close-angle glaucoma, the former one accounts for a higher number of diagnosed Glaucoma cases.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Diagnosed Prevalence of Glaucoma, Type-specific Diagnosed Prevalent Population of Glaucoma, Gender-specific Diagnosed Prevalence of Glaucoma, Age-specific Diagnosed Prevalence of Glaucoma, Type-specific Diagnosed Prevalence of Open-Angle Glaucoma.

GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps

Retrieved on: 
Thursday, July 29, 2021
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Branches of biology, Otorhinolaryngology, Organ systems, Nose, Olfactory system, Sensory organs, Nasal polyp, Respiratory system, Nasal cavity, Polyp, Rhinorrhea, Sinus, chronic rhinosinusitis with nasal polyps (CRSwNP), mepolizumab, GSK, CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP), MEPOLIZUMAB, GSK

It is often characterised by raised eosinophil levels, in which soft tissue growth, known as nasal polyps, develop in the sinuses and nasal cavity.

Key Points: 
  • It is often characterised by raised eosinophil levels, in which soft tissue growth, known as nasal polyps, develop in the sinuses and nasal cavity.
  • CRSwNP can cause chronic symptoms such as nasal obstruction, loss of smell, facial pressure and nasal discharge.
  • GSK is committed to exploring the role of IL-5 inhibition in eosinophil-driven diseases to help address unmet needs of patients.
  • Mepolizumab achieved significant improvement in reducing the size of nasal polyps and nasal obstruction.

Tandem Diabetes Care Announces Upcoming Conference Presentation

Retrieved on: 
Thursday, July 29, 2021
Diabetes, Health, Medical devices, Health, Tandem Diabetes Care, Organ systems, Diabetes, Medicine

The link to the live webcast and archive will be accessible on Tandem Diabetes Cares Investor Center website located at http://investor.tandemdiabetes.com in the Events & Presentations section.

Key Points: 
  • The link to the live webcast and archive will be accessible on Tandem Diabetes Cares Investor Center website located at http://investor.tandemdiabetes.com in the Events & Presentations section.
  • Tandem Diabetes Care, Inc. ( www.tandemdiabetes.com ) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience.
  • Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.
  • Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2, and $TNDM.

Dignitana signs distributor B&Co Group to support Benelux Growth

Retrieved on: 
Thursday, July 29, 2021
Organ systems, Medicine, Clinical medicine, Human hair, Hair diseases, Hair loss, Chemotherapy, Hypothermia cap, Geerts

STOCKHOLM, July 29, 2021 /PRNewswire/ -- Dignitana , world leader in scalp cooling innovation, has signed with leading distributor B&Co Group to drive growth in the Benelux region.

Key Points: 
  • STOCKHOLM, July 29, 2021 /PRNewswire/ -- Dignitana , world leader in scalp cooling innovation, has signed with leading distributor B&Co Group to drive growth in the Benelux region.
  • The agreement kicks off with the sale of two DigniCap devices which are used by cancer centers to minimize hair loss from chemotherapy.
  • "Innovation is a key component of our business, and in that regard, we align well with Dignitana," said Bob Geerts, CEO and Founder of B&Co Group.
  • "The B&Co Group are experts in selling cutting edge medical devices and are known for their commitment to after-sales service and support," said William Cronin, Dignitana CEO.

New Study: Half of Americans Living with Diabetes May be Consuming Less Than the Recommended Amount of Protein, which is Associated with Greater Physical Limitations

Retrieved on: 
Thursday, July 29, 2021
Anatomy, Organ systems, Diabetes, Branches of biology, Disability, Skeletal muscle, Type 1 diabetes

R.D., lead researcher, and professor of Medical Dietetics at The Ohio State University School of Health and Rehabilitation Sciences.

Key Points: 
  • R.D., lead researcher, and professor of Medical Dietetics at The Ohio State University School of Health and Rehabilitation Sciences.
  • "Diabetes is associated with a risk for developing low muscle mass, which can lead to falls and other injuries.
  • That's why protein consumptionand awareness of the need for itis critical to maintaining muscle mass and preserving functional mobility, which can help people living with diabetes live stronger overall lives."
  • FreeStyle Libre 2 system will be list priced the same rate as FreeStyle Libre 14 day system.

Medimaps Announces Reimbursement by Center for Medicare and Medicaid Services (CMS) for Trabecular Bone Score for Osteoporosis Fracture Risk Assessment

Retrieved on: 
Thursday, July 29, 2021
Health, Technology, Managed care, Software, Radiology, Biotechnology, Musculoskeletal disorders, Musculoskeletal system, Organ systems, Osteopathies, Aging-associated diseases, Endocrine diseases, Rheumatology, Osteonecrosis, Osteoporosis, Bone density, Medication-related osteonecrosis of the jaw, Bone fracture

This is the first new reimbursable CPT code for fracture risk assessment in osteoporosis in almost a decade.

Key Points: 
  • This is the first new reimbursable CPT code for fracture risk assessment in osteoporosis in almost a decade.
  • The reimbursement amount was released by CMS last week and will become effective and available January 1, 2022.
  • This is largely a result of the fact that 75% of high-risk patients are not being diagnosed timely4.
  • Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study, Journal of Bone and Mineral Research.

FDA Accepts Application for Genentech’s Faricimab for the Treatment of Wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)

Retrieved on: 
Thursday, July 29, 2021
Research, FDA, Diabetes, Clinical trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Ophthalmology, Organ systems, Vision, Blindness, Diabetes, Diabetic retinopathy, Macular edema, Macular degeneration, Retinopathy, Angiogenesis inhibitors, Anti–vascular endothelial growth factor therapy, the TENAYA and LUCERNE Studies, the YOSEMITE and RHINE Studies, Wet Age-Related Macular Degeneration, Diabetic Macular Edema, faricimab, Genentech in Ophthalmology, Genentech, THE TENAYA AND LUCERNE STUDIES, THE YOSEMITE AND RHINE STUDIES, WET AGE-RELATED MACULAR DEGENERATION, DIABETIC MACULAR EDEMA, FARICIMAB, GENENTECH IN OPHTHALMOLOGY, GENENTECH

Therefore, we hope faricimab will become a new treatment option for millions of people living with wet AMD and DME.

Key Points: 
  • Therefore, we hope faricimab will become a new treatment option for millions of people living with wet AMD and DME.
  • Faricimab is the first injectable eye medicine to achieve this length of time between treatments in Phase III studies for wet AMD and DME.
  • The European Medicines Agency has also validated the faricimab Marketing Authorization Application for the treatment of wet AMD and DME.
  • Affecting approximately 750,000 people in the United States, diabetic macular edema (DME) is a vision-threatening complication of diabetic retinopathy (DR).

HMP Global's Dermatology Week Announces Scholarship Program for Its Inaugural Educational Event

Retrieved on: 
Wednesday, July 28, 2021
Psoriasis, Dermatology, Organ systems, Medical specialties, National Psoriasis Foundation, National Rosacea Society

MALVERN, Pa., July 28, 2021 /PRNewswire-PRWeb/ -- HMP Global, the leading healthcare event and education company, today announced its Education Accelerator Initiative, an expansive scholarship program for the inaugural Dermatology Week event.

Key Points: 
  • MALVERN, Pa., July 28, 2021 /PRNewswire-PRWeb/ -- HMP Global, the leading healthcare event and education company, today announced its Education Accelerator Initiative, an expansive scholarship program for the inaugural Dermatology Week event.
  • Each day's programming is designed to address the needs of specialized dermatologists as well as those treating general patient populations.
  • The program has been developed in conjunction with and endorsed by the Dermatology Nurses' Association (DNA), the National Psoriasis Foundation (NPF) and the National Rosacea Society (NRS).
  • "Dermatology Week will be delivered by outstanding experts from across the nation who are actively shaping the future of dermatological care," said Dr. Gelfand.

Global Cannabidiol Market Size Expected to Reach $2.8 Billion by 2028 with a CAGR of 21%

Retrieved on: 
Wednesday, July 28, 2021
Drugs, Organ systems, Psychoactive drugs, Cannabinoids, Resorcinols, Appetite stimulants, Entheogens, Euphoriants, Cannabidiol, Cannabis, Hemp

A report from Grand View said that the global cannabidiol market size was valued at USD 2.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 21.2% from 2021 to 2028.

Key Points: 
  • A report from Grand View said that the global cannabidiol market size was valued at USD 2.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 21.2% from 2021 to 2028.
  • Grand View added: "Furthermore, the use of hemp-derived CBD is increasing rapidly owing to its anti-inflammatory, anti-aging, and antioxidant properties.
  • This rapidly progressing transformation of cannabidiol from herbal preparations to prescription drugs is anticipated to boost the growth of the market.
  • Furthermore, growing awareness about the medical benefits of cannabidiol, including its healing properties, is anticipated to drive the product demand in the pharmaceutical industry."